Please login to the form below

Not currently logged in
Email:
Password:

clinical trial

This page shows the latest clinical trial news and features for those working in and with pharma, biotech and healthcare.

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

The trial didn’t meet its primary objective at 12 months, as reported last December. ... They estimate– based on Eisai’s earlier communications on the drug and trial design – that the clinical benefit could be around 20-25% and “certainly very

Latest news

  • Anavex sets up trial of ‘triple-action’ Alzheimer’s drug Anavex sets up trial of ‘triple-action’ Alzheimer’s drug

    will enable “enriched clinical trial populations, more robust regulatory submissions and better characterised clinical trial designs.”. ... But the biotech thinks that the broad activity of Anavex 2-73 and biomarker-driven clinical trials elevate its

  • Summit plunges after Duchenne disappointment Summit plunges after Duchenne disappointment

    However while this clinical trial failure was once typical of the DMD field, there are signs of a breakthrough against the life-shortening muscle wasting disease. ... Just last week Sarepta unveiled very early but promising data from a phase I/II

  • The year of the blockbuster The year of the blockbuster

    drug pipelines, patents, clinical trial read-outs, deal documents, company announcements and conference presentations. ... Trial results, regulatory  data, market projections and regulatory designations were all taken into account.

  • Sarepta soars on positive Duchenne data Sarepta soars on positive Duchenne data

    Sarepta soars on positive Duchenne data. Trial results position Sarepta as a “leader in the field”according to analysts. ... Sarepta’s gene therapy for Duchenne muscular dystrophy has produced stellar results in the first three patients treated in

  • More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease

    European Union. later this year, and we continue to work closely with clinical investigators and regulatory authorities to complete our ongoing clinical trials and bring this important treatment option to patients ... These two major clinical trial

More from news
Approximately 8 fully matching, plus 1,027 partially matching documents found.

Latest Intelligence

  • Brave real world? How healthcare communication needs to adapt Brave real world? How healthcare communication needs to adapt

    the stresses and strains of the real world. So how do we ensure that HCPs, regulators and patients understand and value data that has been collected outside a clinical trial? ... Second, we have to be clear when communicating the complexities and

  • Protecting patient privacy Protecting patient privacy

    Phase 2 of Policy 0070, which will require that life science companies provide anonymised copies of all of their clinical trial data, is coming down the line, albeit that currently there ... For clinical trial sponsors, this all adds up to the lowest

  • GDPR and the NHS ‘opt out’: a chance to engage patients in research GDPR and the NHS ‘opt out’: a chance to engage patients in research

    Increased global investment in clinical trials and real-world evidence studies would feed back directly into the economy and into NHS care.”. ... This shift fundamentally makes patients an active participant in their own care; allowing them to

  • A critical juncture for clinical data management A critical juncture for clinical data management

    eTMF) systems with 70% usage and clinical trial management systems (CTMS) with 61% usage. ... Despite the drive toward clinical-data digitalisation, nearly one-third of companies report that they still use paper case-report forms.

  • The rise of real-world evidence The rise of real-world evidence

    The rise of real-world evidence. Demonstrating efficacy and value requires more than clinical trial data. ... Claims data lacks clinical outcomes. Some patient registries are unreliable and have limited follow-up.

More from intelligence
Approximately 1 fully matching, plus 105 partially matching documents found.

Latest appointments

  • Aelix Therapeutics appoints Dr Thomas Hecht Aelix Therapeutics appoints Dr Thomas Hecht

    He said: “Aelix Therapeutics has reached a crucial milestone by enrolling the first patient in the phase I clinical trial and I’m thrilled to be joining the company at this

  • Belgium's TiGenix appoints Dr Gregory Gordon Belgium's TiGenix appoints Dr Gregory Gordon

    TiGenix has also appointed Annette Valles-Sukkar as associate director, clinical projects, and both she and Dr Gordon will report to the company’s chief medical officer Dr Marie Paule Richard. ... Meanwhile, Valles-Sukkar arrives at TiGenix from

  • Nabriva Therapeutics appoints new chief commercial officer Nabriva Therapeutics appoints new chief commercial officer

    Bacterial infections focussed Nabriva Therapeutics has appointed Francesco Maria Lavino as its chief commercial officer ahead of the group’s phase III clinical trial for lefamulin - a potential new treatment for ... Lavino joins the Austrian

  • Multipharma launches Inceptua Medicines Access Multipharma launches Inceptua Medicines Access

    clinical trials of comparator sourcing, strategic planning, global depot solutions and clinical manufacturing. ... With this new addition Multipharma is poised to become a major global provider in the clinical trial services, pre-approval and unlicensed

  • Sam Agus takes up new role at Hansa Medical Sam Agus takes up new role at Hansa Medical

    With experience in medical strategy, multidisciplinary team leadership, medical marketing and clinical trial design, Agus’s therapy area expertise includes neurology, psychiatry, gastroenterology, women’s health and rare diseases.

More from appointments
Approximately 0 fully matching, plus 41 partially matching documents found.

Latest from PMHub

  • Medical information in precision medicine

    It carries out genomic testing and provides a data insight service, which helps doctors match patients to different therapies and clinical trials. ... One way of achieving this collaboration is by engaging with patient organisations and clinical trial

  • Is the pharma business model ready for precision medicine?

    Couple this with a reduction in research and development expenditure, through smaller clinical trial costs and reduced time-to-market, which is estimated to save $26bn annually and the positive impact ... However, despite these developments, clinical

  • Engaging patients in their clinical trial journey

    Consequently, multimedia content in your patients’ own languages is a must for successful clinical trial communication. ... So what is the best way to keep a group of 10 to 16-year-old patients engaged throughout a two-year clinical trial?

  • Challenges of using electronic media with translated content

    For example, a clinical trial newsletter could be sent out using email, posted on a website, or via direct social media, alongside more tradition hard-copy in the post.

  • Investigator meetings deconstructed

    virtually. Distance learning, while not right for every type of meeting, can deliver against numerous obstacles surrounding clinical trial training, particularly often-dull standard presentations or regulatory requirements. ... Investigator meetings can

More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics